Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

BrainChip has added another distribution pathway for its Akida neuromorphic AI technology, signing a non-exclusive, worldwide IP distribution licence with South Korea’s ASICLAND. The deal allows ASICLAND to integrate BrainChip’s Akida IP into custom system-on-chip designs for multiple end customers, provided BrainChip signs off on the relevant licensing approvals.

For investors, the key point is that this is not a single-chip, single-customer arrangement. ASICLAND can use Akida across multiple customer engagements, including evaluation licences and multi-project wafer runs, which are commonly used to produce prototype and test silicon before anyone writes the bigger cheque for commercial deployment. If those customers proceed, the evaluation licences can be converted into production licences, with additional production licence fees payable to BrainChip.

That matters because BrainChip’s long-running challenge has not been invention. Akida has never lacked gee-whiz appeal. The market’s question has been simpler and more brutal: how does the IP turn into recurring revenue?

The model: upfront fees, royalties and optional services

The financial structure is the most investor-relevant part of the deal. BrainChip says the agreement includes upfront evaluation and production licence fees on a per-customer basis, ongoing volume-based royalties calculated on net sales of licensed products, and extra fees for optional services and software maintenance.

The company has not quantified the financial impact, but says it expects revenue to be material over time. That phrase will do some work. It gives investors a direction of travel, but not the speed limit, the distance or whether there are potholes. The valuation significance depends on how many ASICLAND customers move from prototype silicon to production, what end-markets they target, and whether volumes eventually justify meaningful royalty income.

Importantly, BrainChip retains ownership of its IP. ASICLAND is not permitted to sublicense it, meaning the Akida technology is incorporated only within ASICLAND-designed semiconductor products supplied to customers. That is a useful control point for BrainChip, because it keeps the company in the approval chain and preserves the potential to engage directly with end customers for extra support, services or commercial arrangements.

Why ASICLAND matters

ASICLAND is not just a reseller with a glossy brochure. The company is a Korea-based semiconductor design and turnkey services provider, described as a TSMC Value Chain Alliance partner with expertise across AI, memory, IoT/RF and automotive applications. It also has an R&D centre in Hsinchu, Taiwan, and business operations in San Jose in the United States.

That footprint is relevant because custom silicon adoption is rarely a straight line. Customers need design capability, foundry access, integration support and confidence that clever IP can survive the messy business of becoming working silicon. ASICLAND’s role is to help customers cross that bridge from architectural concept to functional chips.

BrainChip chief executive Sean Hehir said the partnership extends the company’s reach into a broader range of custom silicon programs, adding that ASICLAND’s SoC design capabilities and customer relationships make it “a strong partner for accelerating Akida adoption across multiple end markets, while maintaining the integrity of our IP and long-term royalty model.”

Market reaction and context

The deal landed with BRN already a heavily watched stock among Australian tech speculators. ASX company data showed BrainChip with a market capitalisation of about $352.75 million, while external market data showed the shares trading around 16.3 cents, up 0.8 cents or 4.84% during the session.

That pop is understandable. The agreement gives investors something they have long wanted to see: another potential commercial channel for Akida, tied to licence fees and royalties rather than one-off demonstrations. The ASX also listed the BrainChip-ASICLAND release at 9:01am on 4 May 2026, marking it as the company’s main price-sensitive news of the morning.

What investors should watch next

The deal is strategically tidy, but the real test is conversion. Evaluation licences are helpful. Prototype chips are better. Production licences are the prize. The difference between those stages is the difference between “interesting technology platform” and “revenue engine”.

The next markers to watch are customer names, the number of evaluation licences issued through ASICLAND, evidence of MPW prototype activity, conversion into production licences, and any disclosure of royalty-bearing products moving towards commercial manufacture.

For now, BrainChip has strengthened its route-to-market story in edge AI, industrial, automotive, consumer and IoT applications. The company still has to prove that partner ecosystem momentum can translate into material, repeatable revenue. But this deal gives Akida another seat at the silicon table - and for BrainChip shareholders, that is at least a more tangible prospect than another round of AI theme music.

Entropy Neurodynamics has produced the sort of early-stage biotech result that investors notice quickly, although they should still keep both feet planted on the lab floor.

The ASX-listed clinical-stage company reported that its Phase 2a study of TRP-8802, an oral psilocybin therapy used with structured psychotherapy, achieved a 75 percent response rate in treatment-resistant irritable bowel syndrome patients. The trial involved 12 patients who had previously failed multiple standard treatments, with clinical response defined as at least a 50-point reduction on the IBS Symptom Severity Score.

For context, Entropy says approved IBS therapies typically produce response rates of 17 percent to 44 percent, generally in less difficult non-refractory patient groups. That comparison is why the company is calling the result a breakthrough. In biotech parlance, that is a word best handled with tongs, but the signal is undeniably notable for a patient group with few reliable options.

The gut-brain angle

The important part for investors is not just the headline 75 percent number. The study also linked symptom improvement with changes in psychological insight and psychological flexibility, which supports Entropy’s thesis that IBS can be tackled through gut-brain axis modulation rather than simply dampening bowel symptoms.

Subtype results were also eye-catching. Patients with constipation-predominant IBS recorded a 100 percent response rate, albeit from only three patients. Mixed-type IBS delivered four responses from five patients, while diarrhoea-predominant IBS recorded two responses from four patients.

That is interesting rather than definitive. With only 12 patients, one patient can move the percentage dial substantially. Still, early-stage drug development is often about detecting whether there is enough biological smoke to justify looking for fire in a larger, controlled trial. On that measure, Entropy has given itself something to work with.

The safety sting in the tail

The safety readout was broadly described as consistent with expectations for psychedelic-assisted therapy, but it was not event-free. One serious adverse event, transient suicidal ideation, occurred and resolved with clinical support.

That matters. Psychedelic therapy is not a simple pill-in-a-box model. Screening, supervision, integration and clinical infrastructure are central to the treatment approach. For investors, that creates both a barrier to entry and a commercial constraint. A therapy that needs trained clinicians and structured psychotherapy may command premium pricing, but it also carries execution complexity.

TRP-8803 is the real commercial target

While the trial used TRP-8802, the bigger commercial story is TRP-8803, Entropy’s proprietary IV-infused psilocin formulation. The company says the oral psilocybin program was designed to de-risk the indication and mechanism for TRP-8803.

The logic is straightforward. Oral psilocybin can be variable because of metabolism and timing. Entropy argues that IV psilocin could offer faster onset, better control over dose, depth and duration of effect, and a more scalable treatment model. If that proves true, TRP-8803 could be the product with the cleaner clinical and commercial package.

Chief executive Jason Carroll said the data represented “a breakthrough moment for Entropy and for the treatment of IBS”, adding that the 75 percent response rate in a treatment-resistant population was “clinically unprecedented”. He also said the dataset was “mechanistically coherent”, with clinical outcomes aligning with improvements in psychological drivers.

The market carrot is large

Entropy is pointing to a substantial addressable market. The company says IBS affects about 10.4 million patients in the US, where annual spending exceeds US$60 billion, and more than one million patients in Australia. It also says treatment-resistant IBS patients commonly cycle through multiple therapies and can incur meaningful out-of-pocket costs.

That gives the story a familiar biotech shape: a large market, inadequate current options, promising early data and a proprietary next-generation asset. The company also flagged potential partnering discussions, larger trials, grant funding opportunities and a US-focused development path.

The obvious catch is that a 12-patient open-label study is not the same as a randomised, placebo-controlled pivotal trial. Open-label designs are useful for early mechanistic work, but they leave plenty of room for placebo effects, selection bias and over-interpretation. IBS trials can also be noisy, given fluctuating symptoms and the influence of psychological and behavioural factors.

Investor takeaway

For retail investors, Entropy’s result is best viewed as a value-inflection data point, not a finish line. The company has generated a strong early efficacy signal in a difficult indication, with a plausible mechanistic story and a more commercially targeted follow-on asset in TRP-8803.

The next questions are more prosaic but more important: can the response be replicated in a larger controlled trial, can safety be managed at scale, can regulators be satisfied, and can the treatment model work commercially outside specialist centres?

Biotech investors are used to castles being built on mouse studies and mist. This one at least has human data. Now Entropy has to show that the 75 percent signal is not just impressive, but repeatable.

Sprintex has signed an exclusive distribution agreement with Washnah Trading Co. LLC for Saudi Arabia, giving the small-cap clean air technology group a formal channel into one of the world’s most infrastructure-hungry markets.

The agreement covers Sprintex’s G-Series, GA and GR high-speed Jet Blowers across the Kingdom. For investors, the headline number is not immediately huge, but it is tangible: once regulatory approvals are secured, Washnah must deliver minimum secured orders of US$500,000, or about A$701,000, for each 12-month period. Excess orders can be carried forward, which gives the arrangement some flexibility if demand arrives in lumps rather than neat annual parcels.

The initial term runs to 31 March 2029, with a two-year extension available if milestones are met. These milestones include vendor registration with Saudi Arabia’s National Water Company and product approvals via the SABER platform, part of the Saudi Standards, Metrology and Quality Organisation system.

That sounds like regulatory plumbing, and it is. But for industrial equipment suppliers, particularly those selling into government-linked water and wastewater projects, being on the approved vendor list is often the difference between watching the feast and getting a seat at the table.

Airport tender could be the company maker

The sizzle is Washnah’s tender for wastewater treatment works at King Salman International Airport, where Sprintex’s high-speed turbo blowers have been specified exclusively.

The tender includes about 30 Sprintex units ranging from 11 kW to 675 kW, covering process stages such as grease and grit removal, aeration tanks, membrane bioreactor tanks, sludge holding tanks and equalisation tanks. The package also includes acoustic enclosures, control panels with variable frequency drives and program logic controllers, IoT monitoring and commissioning support from Sprintex engineers.

Sprintex puts the potential opportunity at more than A$5 million, based on supply of blower content only. Tender award is expected in the second half of calendar 2026.

For context, Sprintex is a company with a market value of about A$52 million on ASX data and its shares were recently around 7.4 cents, according to market data. That means a single A$5 million equipment opportunity is not pocket change for the company, even allowing for the obvious caveat that a tender is not a purchase order.

Why the airport matters

King Salman International Airport is no ordinary terminal upgrade with new carpet and a brighter duty-free section. The project, based in Riyadh and owned by Saudi Arabia’s Public Investment Fund, is expected to cover 57 square kilometres and include six parallel runways. The airport is targeting capacity of up to 100 million passengers by 2030 and 185 million by 2050.

The official airport site says the development will include six runways, six terminals, a royal terminal, private aviation facilities, a cargo and logistics hub and real estate areas. It is designed as a core plank in Saudi Arabia’s push to turn Riyadh into a global hub for business, tourism and logistics.

For Sprintex, the attractive part is less glamorous than the architecture but arguably more dependable: wastewater treatment. Airports, cities, desalination plants and industrial facilities need continuous-duty systems. In these applications, energy efficiency is not green window dressing - it goes straight to operating costs.

Management talks scale and validation

Sprintex managing director and chief executive Jay Upton described the Saudi agreement and airport tender as “a significant milestone” in the company’s international expansion.

“The scale of the tender - approximately 30 high-power turbo blowers up to 675 kW across the full wastewater treatment works - provides powerful early validation of both our technology platform and the strength of the partnership,” Upton said.

He added that Saudi Vision 2030’s infrastructure programme creates a long-term opportunity for Sprintex’s energy-efficient blower solutions.

That is the nub of the investment case. Sprintex has been repositioning from its better-known automotive supercharger heritage toward industrial clean air applications, including wastewater, aquaculture, paper milling, pharmaceuticals and clean energy compressors. The Saudi deal gives it a local partner, a defined market and a flagship project to chase.

What investors should watch next

The next milestones are clear enough: Saudi regulatory approvals, National Water Company vendor registration, conversion of the airport tender into an awarded contract and evidence that Washnah can build a recurring pipeline beyond the glamour project.

The risk is equally clear. The A$5 million tender remains contingent, and large infrastructure projects can move with all the speed of a camel in a sandstorm when procurement, approvals and government priorities are involved. Minimum annual orders only kick in after approvals, so investors should be careful not to bank the revenue before the paperwork lands.

Still, for a sub-A$100 million ASX industrial technology stock, this is a credible door-opener. Sprintex now has exclusivity in Saudi Arabia, a local partner with wastewater sector relationships, minimum order commitments and a tender tied to one of the Middle East’s highest-profile infrastructure builds.

The runway is long, but at least Sprintex has found a gate.

Swift TV Ltd has given small-cap investors something more tangible than the usual tech-sector promise jar: installed hardware, contracted sites and a near-term deployment timetable. The company says 2,758 Swift TV screens have been installed across seven customer sites in just seven weeks, spanning resources and aged care customers, including global oil and gas operators and leading aged care providers. A further eight sites are scheduled for completion by 1 June 2026.

That matters because Swift has been trying to shift the investor conversation from “product development” to “commercial rollout”. In microcap tech, that transition is often where the wheels either start turning or fall off entirely. Swift is now arguing the former.

Recurring revenue is the prize

The key phrase for investors is recurring subscription revenue. Swift says revenue commences or expands as each site is commissioned, with deployments typically supported by multi-year contracts. That is a more attractive model than lumpy hardware sales, assuming the company can keep installation costs, support costs and churn under control.

The company does not provide contract values, average revenue per screen, gross margins or payback periods, so investors are still being asked to fill in a fair few blanks. But the operational metric is worth watching: 2,758 screens in seven weeks suggests the rollout process is no longer a lab exercise.

Chief executive Brian Mangano put it plainly, saying: “The speed of deployment we are seeing is a strong validation of the Swift TV platform and marks a clear transition from product development to commercial rollout.” He added that installing more than 2,700 screens in seven weeks showed the company’s ability to scale across multiple sites and that Swift is focused on converting deployments into recurring subscription revenue.

The 5,000-unit order is a confidence signal - with a caveat

Swift has also ordered another 5,000 units from a Google certified supplier to support its near-term pipeline. On one hand, that is a useful sign that management sees enough contracted or prospective demand to warrant inventory build-up. On the other hand, investors should watch the balance sheet implications.

Hardware orders cost money before revenue arrives. The company has not disclosed the unit cost, payment terms or whether customer contracts carry upfront contributions. For a company of Swift’s size, execution is not just about selling screens - it is about funding the rollout without squeezing working capital too hard.

At the time of writing, ASX data showed Swift shares at $0.009, with a market capitalisation of about $11.25 million. That valuation leaves little room for heroic assumptions, but it also means any credible growth in contracted recurring revenue could become material.

Why mining camps and aged care make sense

Swift’s chosen sectors are not random. Mining, oil and gas, aged care and hospitality all involve residents, workers or guests spending extended time in managed accommodation. That creates a natural use case for in-room entertainment, communications, messaging and engagement tools.

For resources customers, the attraction is likely to be workforce engagement and site communications, especially in remote camps where amenity can help with retention. For aged care operators, the platform may help with resident entertainment, family engagement and facility communications. Swift describes its product as an all-in-one connected TV platform designed to unify entertainment, communication and engagement, with integrations aimed at improving business outcomes.

The strategic logic is tidy enough. The investor question is whether Swift can turn that logic into scalable margins.

The next milestones

There are three things investors should watch from here. First, whether the eight additional sites due by 1 June are completed on schedule. Second, whether Swift starts providing harder revenue metrics, such as annualised recurring revenue, revenue per screen, contract length and gross margin. Third, whether the 5,000-unit order translates into commissioned sites rather than sitting in inventory like a very modern-looking Christmas tree pile.

Swift has not yet given the market the full economics of the rollout. But it has provided a clearer operational scoreboard. Screens are being installed, customers are being commissioned and the company says recurring revenue is now beginning to flow or expand as sites go live.

For a sub-$15 million ASX technology company, that is a meaningful step. The next job is to prove that scale can come with cash flow, not just more screens on walls.

Adisyn has moved quickly to turn a burst of technical and strategic momentum into cash, lining up a placement of up to 207.4 million shares at 6.75 cents each, which works out to about $14 million before costs. Of that total, 204.4 million shares can be issued under the company’s existing placement capacity, while a further 2.96 million shares for director participation remain subject to shareholder approval. The proposed issue date for the main tranche is 30 April 2026, with the director component to be put to holders on 11 June 2026.

For existing investors, the first point is that this is not a token top-up. It is a meaningful capital raising that will expand the register and reshape the balance sheet. Using ASX’s quoted market capitalisation of $61.72 million and a last price of 7.5 cents, the placement equates to roughly one new share for every four already on issue - a dilution event of about 25%. That is not trivial, but neither is the cheque being written. In small-cap land, a raise of this size usually tells you one of two things: the company is plugging a hole, or institutions think there is enough in the story to fund the next leg properly. Adisyn is clearly pitching the latter.

Institutions are not just turning up - they are cornerstoning it

What lifts this above the run-of-the-mill placement is the identity of the backers. The company says the raising was cornerstoned by Regal Funds Management and Meitav, described as Israel’s largest investment house. That matters because institutional names can act as a form of external validation, particularly for a company whose appeal rests on commercialising advanced materials rather than churning out near-term cash flow. The placement was also led by Sandton Capital Advisory, which will receive a 6% fee, and the director participation totals about $200,000, subject to approval.

The price itself was not especially punitive by small-cap standards. Adisyn says the 6.75 cent issue price represents a 10% discount to the last closing price of 7.0 cents on 21 April 2026 and a 5.78% discount to the 15-day VWAP. In other words, the company raised serious money without having to serve up a bargain-bin special. That suggests the book was supported by investors willing to pay close to market for exposure to the story, which is often a better sign than a deeply discounted rescue mission.

Why the market was prepared to stump up

The timing is no accident. Adisyn has just come off the back of two eye-catching developments. First, it reported a low-temperature graphene deposition result using an industrial atomic layer deposition system, which the company argues is an important step toward semiconductor interconnect applications. Second, it secured exclusive worldwide rights from Tel Aviv University’s commercialisation arm to graphene-based radar absorption technology aimed at defence and drone applications. Together, the pair broaden the investment case from pure lab promise to something closer to a platform story with semiconductor and defence angles.

That does not mean the technology risk has vanished. Far from it. Graphene has a long and colourful history of exciting presentations and limited commercial payoff. What Adisyn has done, though, is give investors two reasons to believe the company may have edged closer to a real addressable market. The semiconductor result goes to manufacturability and process compatibility, while the radar-absorbing materials deal points to a separate, defence-flavoured commercial pathway. When a company can pitch two potentially valuable verticals at once, it tends to get a better hearing from institutions.

What to watch next

The near-term checklist is straightforward. Investors will want to see the main tranche settle and allot on schedule, director participation approved, and - most importantly - evidence that the fresh cash is producing commercial progress rather than just extending the corporate runway. The funds are earmarked for graphene technology programs, business development, working capital and offer costs. That is sensible enough, but broad enough that management now needs to show tangible milestones. A bigger register and a fatter bank account buy time. They do not buy forgiveness forever.